Welcome to LookChem.com Sign In|Join Free
  • or
Piperazine-1,4-diethylamine, also known as 1,4-bis(2-ethylhexyl)piperazine, is a chemical compound with a molecular formula of C14H32N2. It is often utilized in the synthesis of other chemicals, particularly pharmaceutical products. This colorless liquid at room temperature has a mild odor and is soluble in most organic solvents. Due to its corrosive nature, it can cause significant eye, skin, and respiratory irritation, and may have harmful effects if swallowed or inhaled, necessitating careful handling.

6531-38-0

Post Buying Request

6531-38-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6531-38-0 Usage

Uses

Used in Pharmaceutical Industry:
Piperazine-1,4-diethylamine is used as a chemical intermediate for the synthesis of various pharmaceutical products. Its role in the production process is crucial for creating a range of medications that can address different health conditions.
Used in Chemical Synthesis:
In the chemical industry, Piperazine-1,4-diethylamine is used as a reagent in the synthesis of other complex chemical compounds. Its versatility in chemical reactions makes it a valuable component in the creation of a wide array of products.

Check Digit Verification of cas no

The CAS Registry Mumber 6531-38-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,5,3 and 1 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 6531-38:
(6*6)+(5*5)+(4*3)+(3*1)+(2*3)+(1*8)=90
90 % 10 = 0
So 6531-38-0 is a valid CAS Registry Number.
InChI:InChI=1/C8H20N4/c9-1-3-11-5-7-12(4-2-10)8-6-11/h1-10H2

6531-38-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-[4-(2-aminoethyl)piperazin-1-yl]ethanamine

1.2 Other means of identification

Product number -
Other names Piperazine-1,4-diethylamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6531-38-0 SDS

6531-38-0Synthetic route

2‐[4‐(cyanomethyl)piperazin‐1‐yl]acetonitrile
5623-99-4

2‐[4‐(cyanomethyl)piperazin‐1‐yl]acetonitrile

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

Conditions
ConditionsYield
With lithium aluminium tetrahydride In tetrahydrofuran for 4h; Reflux;87%
Stage #1: 2‐[4‐(cyanomethyl)piperazin‐1‐yl]acetonitrile With lithium aluminium tetrahydride In tetrahydrofuran for 3h; Heating / reflux;
Stage #2: With potassium hydroxide In tetrahydrofuran; water
80%
With ammonia; hydrogen; nickel In ethanol at 20℃;73%
N,N'-bis(2-phthalimidoethyl)piperazine
20541-87-1

N,N'-bis(2-phthalimidoethyl)piperazine

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

Conditions
ConditionsYield
With potassium hydroxide; sodium hydroxide at 300 - 330℃;75%
With hydrogenchloride at 130℃; im Rohr;
With hydrazine hydrate
With hydrazine
ethyleneimine
151-56-4

ethyleneimine

aminoethylpiperazine
140-31-8

aminoethylpiperazine

A

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

B

1-<2-(2-aminoethyl)aminoethyl>piperazine
24028-46-4

1-<2-(2-aminoethyl)aminoethyl>piperazine

Conditions
ConditionsYield
With hydrogenchloride In water at 50℃;A 79.5 % Chromat.
B 20.5 % Chromat.
With hydrogenchloride In water at 25℃; Kinetics; Thermodynamic data; acid-catalyzed ring opening reactions at various temperature, Ea, ΔH are given;
With hydrogenchloride In water at 40℃;A 80.0 % Chromat.
B 20.0 % Chromat.
piperazine-N.N'-diacetic acid dinitrile

piperazine-N.N'-diacetic acid dinitrile

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

Conditions
ConditionsYield
With ethanol; sodium
Glyoxal
131543-46-9

Glyoxal

triethylentetramine
112-24-3

triethylentetramine

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

Conditions
ConditionsYield
With sodium tetrahydroborate In ethanol at -10℃; for 2h;
With sodium tetrahydroborate
With sodium tetrahydroborate In ethanol at 0℃; for 2h;
N,N'-Bis(2-phthalimidoethyl)ethylene diamine
84429-08-3

N,N'-Bis(2-phthalimidoethyl)ethylene diamine

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 61 percent / potassium carbonate / 0.17 h / 132 °C
2: 75 percent / aq.sodium hydroxide, potassium hydroxide / 300 - 330 °C
View Scheme
triethylentetramine
112-24-3

triethylentetramine

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 65 percent / 195 °C
2: 61 percent / potassium carbonate / 0.17 h / 132 °C
3: 75 percent / aq.sodium hydroxide, potassium hydroxide / 300 - 330 °C
View Scheme
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

C15H11NO3

C15H11NO3

C38H38N6O4

C38H38N6O4

Conditions
ConditionsYield
In ethanol at 80℃; for 8h;92%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

nickel(II) perchlorate hexahydrate

nickel(II) perchlorate hexahydrate

(3-[4-(3-aminopropyl)-piperazin-1-yl]-propylamine)nickel(II) perchlorate

(3-[4-(3-aminopropyl)-piperazin-1-yl]-propylamine)nickel(II) perchlorate

Conditions
ConditionsYield
In methanol refluxed for 2 h; ppt. filtered, washed with cold MeOH, dried; elem. anal.;90%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

3,5-di-tert-butyl-2-hydroxybenzaldehyde
37942-07-7

3,5-di-tert-butyl-2-hydroxybenzaldehyde

N,N'-bis{2-[(2-ethylimino)methyl]-4,6-di-tert-butylphenol}piperazine

N,N'-bis{2-[(2-ethylimino)methyl]-4,6-di-tert-butylphenol}piperazine

Conditions
ConditionsYield
In ethanol for 3h; Reflux;87%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

salicylaldehyde
90-02-8

salicylaldehyde

1,4-bis(2-salicylideneaminoethyl)piperazine
80744-39-4

1,4-bis(2-salicylideneaminoethyl)piperazine

Conditions
ConditionsYield
In methanol for 3h; Cooling with ice;87%
thiophene-2-carbaldehyde
98-03-3

thiophene-2-carbaldehyde

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

N,N'-bis[2-(thiophen-2-ylmethyleneamino)ethyl]piperazine
1207281-39-7

N,N'-bis[2-(thiophen-2-ylmethyleneamino)ethyl]piperazine

Conditions
ConditionsYield
In ethanol for 3h; Reflux;86%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

5-bromosalicyclaldehyde
1761-61-1

5-bromosalicyclaldehyde

N,N'-bis{2-[(2-ethylimino)methyl]-5-bromophenol}piperazine
1207281-37-5

N,N'-bis{2-[(2-ethylimino)methyl]-5-bromophenol}piperazine

Conditions
ConditionsYield
In ethanol for 3h; Reflux;85%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

phthalic anhydride
85-44-9

phthalic anhydride

N,N'-bis(2-phthalimidoethyl)piperazine
20541-87-1

N,N'-bis(2-phthalimidoethyl)piperazine

Conditions
ConditionsYield
In acetic acid Condensation; Heating;80%
pyridine-2-carbaldehyde
1121-60-4

pyridine-2-carbaldehyde

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

N-((1-pyridin-2-yl)formylidene)-N'-[2-(4-[2-[((1-pyridin-2-yl)formylidene)amino]ethyl]piperazin-1-yl)ethyl]amine
917590-68-2

N-((1-pyridin-2-yl)formylidene)-N'-[2-(4-[2-[((1-pyridin-2-yl)formylidene)amino]ethyl]piperazin-1-yl)ethyl]amine

Conditions
ConditionsYield
In ethanol for 3h; Reflux;80%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

salicylaldehyde
90-02-8

salicylaldehyde

N,N'-bis{2-[(2-ethylimino)methyl]phenol}piperazine
78186-31-9

N,N'-bis{2-[(2-ethylimino)methyl]phenol}piperazine

Conditions
ConditionsYield
In ethanol for 3h; Reflux;80%
In methanol for 3h; Cooling with ice;
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

phenyl(pyridin-2-yl)methanone
91-02-1

phenyl(pyridin-2-yl)methanone

N-((1-pyridin-2-yl)benzylidene)-N'-[2-(4-[2-[((1-pyridin-2-yl)benzylidene)amino]ethyl]piperazin-1-yl)-ethyl]amine
959850-48-7

N-((1-pyridin-2-yl)benzylidene)-N'-[2-(4-[2-[((1-pyridin-2-yl)benzylidene)amino]ethyl]piperazin-1-yl)-ethyl]amine

Conditions
ConditionsYield
for 7h; Reflux;79.1%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

9-methylphenazine-1-carboxylic acid imidazolide
343247-31-4

9-methylphenazine-1-carboxylic acid imidazolide

C36H36N8O2

C36H36N8O2

Conditions
ConditionsYield
In tetrahydrofuran at 20℃;77%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

4,7-dichloroquinoline
86-98-6

4,7-dichloroquinoline

N-(2-(4-(2-aminoethyl)piperazin-1-yl)ethyl)-7-chloroquinolin-4-amine
1416359-97-1

N-(2-(4-(2-aminoethyl)piperazin-1-yl)ethyl)-7-chloroquinolin-4-amine

Conditions
ConditionsYield
In neat (no solvent) at 80 - 125℃; for 3h;76%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

3-nitro-1,8-naphthalic anhydride
3027-38-1

3-nitro-1,8-naphthalic anhydride

C32H26N6O8
500865-45-2

C32H26N6O8

Conditions
ConditionsYield
In ethanol; toluene for 4h; Reflux;73%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

3‐acetyl‐2‐hydroxy‐6‐methyl‐4H‐pyran‐4‐one
16807-48-0

3‐acetyl‐2‐hydroxy‐6‐methyl‐4H‐pyran‐4‐one

((3E,3'E)-3,3'-(((piperazine-1,4-diylbis(ethane-2,1-diyl))bis(azanediyl))bis(ethan1-yl-1-ylidene))bis(6-methyl-2H-pyran-2,4(3H)-dione))

((3E,3'E)-3,3'-(((piperazine-1,4-diylbis(ethane-2,1-diyl))bis(azanediyl))bis(ethan1-yl-1-ylidene))bis(6-methyl-2H-pyran-2,4(3H)-dione))

Conditions
ConditionsYield
In ethanol for 24h;63%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

5-((Z)-4-hydroxybenzylidene)-2-methylmercapto-4-thiazolidinone
521973-02-4

5-((Z)-4-hydroxybenzylidene)-2-methylmercapto-4-thiazolidinone

(5Z,5'Z)-2,2'-[piperazine-1,4-diylbis(ethane-2,1-diylimino)]bis(5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one)
1415582-35-2

(5Z,5'Z)-2,2'-[piperazine-1,4-diylbis(ethane-2,1-diylimino)]bis(5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one)

Conditions
ConditionsYield
In ethanol for 8h; Reflux;58%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

9-Chloro-N-<2-(dimethylamino)ethyl>acridine-4-carboxamide
89459-23-4

9-Chloro-N-<2-(dimethylamino)ethyl>acridine-4-carboxamide

C44H54N10O2

C44H54N10O2

Conditions
ConditionsYield
In phenol at 125℃; for 2h;48%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

p-benzyloxybenzenesulfonyl chloride
87001-32-9

p-benzyloxybenzenesulfonyl chloride

N,N'-(2,2'-(piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-(benzyloxy)benzenesulfonamide)

N,N'-(2,2'-(piperazine-1,4-diyl)bis(ethane-2,1-diyl))bis(4-(benzyloxy)benzenesulfonamide)

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 2h;47%
pyridine-2-carbaldehyde
1121-60-4

pyridine-2-carbaldehyde

1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

cobalt(II) perchlorate hexahydrate

cobalt(II) perchlorate hexahydrate

CoBrC4H8N2(CH2CH2NCHC5H4N)2(1+)*ClO4(1-)=CoBrC4H8N2(CH2CH2NCHC5H4N)2ClO4

CoBrC4H8N2(CH2CH2NCHC5H4N)2(1+)*ClO4(1-)=CoBrC4H8N2(CH2CH2NCHC5H4N)2ClO4

Conditions
ConditionsYield
With NaOH In methanol abs. MeOH soln. of NaOH added to abs. MeOH soln. of piperazine deriv.; stirred at room temp. for a few min; filtered off; washed with abs. MeOH;added dropwise to hot abs. MeOH soln. of Co(ClO4)2, and py-2-CHO over a period of 1 h; refluxed for 18 h; concd.; pptd. by addn. of Et2O; filtered; washed with cold Et2O; dried; elem. anal.;43%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

N-(N-methylpiperidin-4-yl)-9-chloroacridine-4-carboxamide
1030022-78-6

N-(N-methylpiperidin-4-yl)-9-chloroacridine-4-carboxamide

N,N-bis{4-[N-(N-methylpiperidin-4-yl)carbamoyl]acridin-9-yl}-[1,4-bis(2-aminoethyl)-piperazine]
1030022-76-4

N,N-bis{4-[N-(N-methylpiperidin-4-yl)carbamoyl]acridin-9-yl}-[1,4-bis(2-aminoethyl)-piperazine]

Conditions
ConditionsYield
In phenol at 125℃; for 2h;35%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

N-[2-(4-morpholinyl)ethyl]-9-chloroacridine-4-carboxamide
646072-61-9

N-[2-(4-morpholinyl)ethyl]-9-chloroacridine-4-carboxamide

C48H58N10O4

C48H58N10O4

Conditions
ConditionsYield
In phenol at 125℃; for 2h;31%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

3-(butylamino)-5-(1H-imidazole-1-carbonyl)-2-phenoxybenzenesulfonamide
1021869-65-7

3-(butylamino)-5-(1H-imidazole-1-carbonyl)-2-phenoxybenzenesulfonamide

C25H38N6O4S
1021869-54-4

C25H38N6O4S

Conditions
ConditionsYield
In dichloromethane at 25℃; under 760.051 Torr;20.46%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

formaldehyd
50-00-0

formaldehyd

β-naphthol
135-19-3

β-naphthol

(13,13'-piperazine-(N,N,N''',N'''-tetra((2-hydroxynaphthyl)methyl))ethane)amine

(13,13'-piperazine-(N,N,N''',N'''-tetra((2-hydroxynaphthyl)methyl))ethane)amine

Conditions
ConditionsYield
In methanol; water for 0.5h; Condensation;13%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

ethyl (2E)‐2‐(hydroxyimino)acetate
31767-15-4

ethyl (2E)‐2‐(hydroxyimino)acetate

(2E)-2-(N-hydroxyimino)-N-[2-(4-{2-[(2E)-2-(N-hydroxyimino)acetamido]ethyl}piperazin-1-yl)ethyl]acetamide

(2E)-2-(N-hydroxyimino)-N-[2-(4-{2-[(2E)-2-(N-hydroxyimino)acetamido]ethyl}piperazin-1-yl)ethyl]acetamide

Conditions
ConditionsYield
In ethanol at 90℃; for 48h;10%
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

4-bromo-6-methoxy-2-methylquinoline
856095-00-6

4-bromo-6-methoxy-2-methylquinoline

A

1-(2-amino-ethyl)-4-[2-(6-methoxy-2-methyl-[4]quinolylamino)-ethyl]-piperazine

1-(2-amino-ethyl)-4-[2-(6-methoxy-2-methyl-[4]quinolylamino)-ethyl]-piperazine

B

1,4-bis-[2-(6-methoxy-2-methyl-[4]quinolylamino)-ethyl]-piperazine

1,4-bis-[2-(6-methoxy-2-methyl-[4]quinolylamino)-ethyl]-piperazine

Conditions
ConditionsYield
at 170℃;
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

4-bromo-6-methoxy-2-methylquinoline
856095-00-6

4-bromo-6-methoxy-2-methylquinoline

1,4-bis-[2-(6-methoxy-2-methyl-[4]quinolylamino)-ethyl]-piperazine

1,4-bis-[2-(6-methoxy-2-methyl-[4]quinolylamino)-ethyl]-piperazine

Conditions
ConditionsYield
at 160℃;
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

1,4-bis-(2-isocyano-ethyl)-piperazine

1,4-bis-(2-isocyano-ethyl)-piperazine

Conditions
ConditionsYield
With sodium hydroxide; chloroform
1,4-bis(2-aminoethyl)piperazine
6531-38-0

1,4-bis(2-aminoethyl)piperazine

9-Chloroacridine
1207-69-8

9-Chloroacridine

C34H34N6
97614-83-0

C34H34N6

Conditions
ConditionsYield
With phenol at 100℃;

6531-38-0Relevant academic research and scientific papers

Bis-aminals of linear tetraamines: Kinetic and thermodynamic aspects of the condensation reaction

Chuburu, Francoise,Tripier, Raphael,Le Baccon, Michel,Handel, Henri

, p. 1050 - 1055 (2003)

The kinetic and thermodynamic aspects of the condensation reaction of dicarbonyl compounds with linear tetraamines were examined in the light of identification of intermediates and DFT calculations. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, German

Metal ion substitution and aldehyde exchange for CuII4 aggregates from two types of piperazine-based Schiff base ligands: Synthesis, X-ray structures, magnetic studies and theoretical validation

Basak, Dipmalya,Ray, Debashis

, (2020)

Two new tetranuclear CuII complexes [Cu4(L2)2(μ2-OH)2(H2O)2]·(ClO4)2·DMF·2H2O (1) and [Cu4(L3)2(μ2-OH)2(H2O)2]·(ClO4)2·DMF·H2O (2) have been synthesized containing piperazine based Schiff base ligands H2L2 (asymmetric) and H2L3 (symmetric). H2L2 contains one o-vanillin and a salicylaldehyde unit while H2L3 has two o-vanillin units. An interesting synthetic methodology involving transition metal ion induced aldehyde exchange reaction between two Schiff base ligands has been explored for the synthesis of H2L2 and H2L3. While the latter can be obtained by direct condensation of the respective amine and aldehyde, the former can only be synthesized by this procedure developed. Both 1 and 2 contain a piperazine ring bridging two CuII centers in chair conformation in the rare axial-equatorial mode of coordination. Two piperazine bridged Cu2 moieties are further connected via two hydroxido and two phenoxido bridges. Of the two Ophenoxido–Cu bonds one is short (basal) and the other is long (apical) while the hydroxido O bridges the two CuII centers symmetrically in basal–basal manner giving rise to a unique [Cu2O2] moiety where, of the four bonds linking the metals, three are basal (short) and one axial (long). Magnetic studies reveal weak antiferromagnetic interactions across the two piperazine bridges with an average exchange constant value of ?4.007 cm?1 and ?4.507 cm?1 for 1 and 2 respectively. The antiferromagnetic exchanges across the phenoxido–hydroxido bridges were found to be stronger with the average value being ?43.036 cm?1 for 1 and ?38.031 cm?1 for 2. Computational studies further support the experimental findings and the spin density plots in the HS configuration reveal that the exchange across the piperazine bridge takes place via through space mechanism. The spin density analysis in the HS and BS configurations also reveal that the exchange interaction is propagated mainly through the hydroxido bridge. The unsymmetrical nature of H2L2 leads to greater spin density at the hydroxido bridge in 1 leading to slightly stronger exchange interaction.

Syntheses and crystal structures of Ni(II) complexes with pyridine-based macrocyclic ligands

Císa?ová, Ivana,Draho?, Bohuslav,Zahradníková, Eva

supporting information, (2021/11/17)

Three pyridine-based macrocyclic ligands, two containing one pyridine pendant arm (L1 and L2) and one containing piperazine rings in the macrocyclic scaffold (L3), with an increasing size of the macrocycle from 12-, 14- to 30-membered ring for L1–L3 were synthesized and characterized. A series of Ni(II) complexes with all these ligands, with molecular formulas [NiL1(CH3OH)](ClO4)2 (1), [NiL2(CH3CN)](ClO4)2 (2), and [Ni2L3(DMF)2(CH3CN)2](ClO4)4 (3) (DMF = N,N–dimethylformamide), was prepared and thoroughly characterized. Single crystal X-ray structural analysis confirmed that all the complexes have a coordination number of six and their geometries are close to octahedral. In the case of the mononuclear complexes 1 and 2, all the nitrogen atoms of the macrocycle are coordinated, however, in the dinuclear complex 3 with the piperazine-based ligand L3, two nitrogen donor atoms (of the total number of ten) are uncoordinated. The first coordination spheres of all the complexes are completed by solvent molecules. The values of effective magnetic moments, determined by the Evans method in solution, are 3.12, 3.19 and 4.36 μB for complexes 1, 2 and 3, respectively, which correspond well to the theoretical spin-only values.

CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM

-

Page/Page column 38; 41; 45-46, (2020/12/07)

In alternative embodiments, provided are uncharged bis-oxime antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). In alternative embodiments, provided are pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound as provided herein.

The effect of the structure of derivatives of nitrogen-containing heterocycles on their anti-influenza activity

Gridina, Tatyana L.,Fedchuk, Alla S.,Basok, Stephan S.,Artemenko, Anatoliy G.,Ognichenko, Liudmila N.,Shitikova, Larisa I.,Lutsyuk, Anatolii F.,Gruzevskii, Aleksandr A.,Kuz’min, Victor E.

, p. 455 - 462 (2019/06/20)

[Figure not available: see fulltext.] An adequate QSAR model based on the simplex representation of the molecular structure was built in order to optimize the search for new anti-influenza agents. Structural interpretation of the model allowed us to identify molecular fragments that determine the activity of compounds against human influenza viruses. Further virtual screening and targeted synthesis allowed us to select a group of potentially effective compounds, three of which, derivatives of piperidine and isoindoline, turned out to be the most promising.

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

-

Page/Page column 219-220, (2010/08/04)

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract

Structure and dimensionality of coordination complexes correlated to piperazine conformation: From discrete [CuII2] and [CuII4] complexes to a μ1,3-N 3- bridged [CuII2]n chain

Paital, Alok Ranjan,Mandal, Debashree,Huang, Xiaoying,Li, Jing,Aromi, Guillem,Ray, Debashis

supporting information; scheme or table, p. 1352 - 1362 (2009/06/05)

Three different types of copper(ii) complexes have been studied of the hexadentate Schiff base ligand N,N′-bis[2-{(salicylidenimine)amino}ethyl] piperazine (H2L) having the piperazine backbone in the chair form and axial-axial (a,a) N-atom lone pairs in the free state. The structure of the products is influenced by the reaction conditions and by the exogenous ligands, affecting the conformation of the piperazine moiety (primary structure) and the topology and nuclearity of the resulting complexes (secondary structure). In [Cu2L(DMF)2]X2 (X = ClO4 -, 1a; NO3-, 1b), the lone-pairs of chair-piperazine adopt the equatorial-equatorial (e,e) conformation. In the presence of NEt3 and NaN3, two types of [Cu II4] complexes [Cu4(L)2(OH) 2(H2O)2]X2·nH2O (X = ClO4-, n = 1, 2a; X = NO3-, n = 4, 2b) and [Cu4(L)2(N3)2(H 2O)2]X2·H2O (X = ClO 4-, 3a; NO3-, 3b) are obtained where four copper(ii) ions are bridged by two hexadentate μ3-piperazine ligands, this time in chair-e,a conformation, and by two OH and N3 groups. In CH3CN, reactions of 1, 2 or 3 with NaN3 always produce the double end-to-end azido bridged 1D polymer [Cu2L(N 3)2]n (4) having a chair-e,e piperazine backbone. All studied conformations of the piperazine bridge mediate antiferromagnetic interactions between the Cu(ii) ions, as revealed by bulk magnetization measurements. The striking difference in intensity of the coupling through trans-e,e piperazine observed for complexes 1a and 4 might be due to complementarily effects between the ligands involved.

Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors

Filosa, Rosanna,Peduto, Antonella,Di Micco, Simone,Caprariis, Paolo de,Festa, Michela,Petrella, Antonello,Capranico, Giovanni,Bifulco, Giuseppe

experimental part, p. 13 - 24 (2011/02/25)

A series of bisnaphthalimide derivatives were synthesized and evaluated for growth-inhibitory property against HT-29 human colon carcinoma. The N,N′-bis[2-(5-nitro-1,3-dioxo-2,3-dihydro-1H-benz[de]-isoquinolin- 2-yl)]propane-2-ethanediamine (9) and the N,N′-Bis[2-(5-nitro-1,3-dioxo-2,3-dihydro-1H-benz[de]-isoquinolin- 2-yl)]butylaminoethyl]-2-propanediamine (12) derivatives emerged as the most potent compounds of this series. Molecular modelling studies indicated that the high potency of 12, the most cytotoxic compound of the whole series, could be due to larger number of intermolecular interactions and to the best position of the naphthalimido rings, which favours π-π stacking interactions with purine and pyrimidine bases in the DNA active site. Moreover, 12 was designed as a DNA topoisomerase II poison and biochemical studies showed its effect on human DNA topoisomerase II. We then selected the compounds with a significant cytotoxicity for apoptosis assay. Derivative 9 was able to induce significantly apoptosis (40%) at 0.1 μM concentration, and we demonstrated that the effect on apoptosis in HT-29 cells is mediated by caspases activation.

Novel combi-molecules having EGFR and DNA targeting properties

-

Page/Page column 14; 24, (2010/02/15)

A series of new chemical agents that demonstrate anti-tumor activity are described. The new chemical agents combine two major mechanisms of anti-tumor action. In an embodiment, the agents are capable of both inhibiting EGFR and damaging DNA while also, upon degradation, degrading to an inhibitor of EGFR and to an agent capable of damaging DNA. Moreover, a novel series of molecules capable of releasing two moles of EGFR inhibitor and a potent bi-functional alkylating agent are also described.

Bisintercalating Threading Diacridines: Relationships between DNA Binding, Cytotoxicity, and Cell Cycle Arrest

Wakelin, Laurence P. G.,Bu, Xianyong,Eleftheriou, Alexandra,Parmar, Alpesh,Hayek, Charbel,Stewart, Bernard W.

, p. 5790 - 5802 (2007/10/03)

We have synthesized a series of bis(9-aminoacridine-4-carboxamides) linked via the 9-position with neutral flexible alkyl chains, charged flexible polyamine chains, and a semirigid charged piperazine-containing chain. The carboxamide side chains comprise N,N-dimethylaminoethyl and ethylmorpholino groups. The compounds are designed to bisintercalate into DNA by a threading mode, in which the side chains are intended to form hydrogen-bonding contacts with the O6/N7 atoms of guanine in the major groove, and the linkers are intended to lie in the minor groove. By this means, we anticipate that they will dissociate slowly from DNA, and be cytotoxic as a consequence of template inhibition of transcription. The dimers remove and reverse the supercoiling of closed circular DNA with helix unwinding angles ranging from 26° to 46°, confirming bifunctional intercalation in all cases, and the DNA complexes of representative members dissociate many orders of magnitude more slowly than simple aminoacridines. Cytotoxicity for human leukemic CCRF-CEM cells was determined, the most active agents having IC50 values of 35-50 nM in a range extending over 20-fold, with neither the dimethylaminoethyl nor the ethylmorpholino series being intrinsically more toxic. In common with established transcription inhibitors, the morpholino series, with one exception, have no effect on cell cycle distribution in randomly dividing CCRF-CEM populations. By contrast, the dimethylaminoethyl series, with two exceptions, cause G2/M arrest in the manner of topoisomerase poisons, consistent with possible involvement of topoisomerases in their mode of action. Thus, the cellular response to these bisintercalating threading agents is complex and appears to be determined by both their side chain and linker structures. There are no simple relationships between structure, cytotoxicity, and cell cycle arrest, and the origins of this complexity are unclear given that the compounds bind to DNA by a common mechanism.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 6531-38-0